Comparative Pharmacology
Head-to-head clinical analysis: FORBAXIN versus NEO RX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FORBAXIN versus NEO RX.
FORBAXIN vs NEO-RX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FORBAXIN is a prodrug of the active moiety cefditoren, a cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibition of protein synthesis in susceptible bacteria.
IV: 500 mg every 12 hours, infused over 30 minutes.
100 mg intravenously every 12 hours.
None Documented
None Documented
8-12 hours; prolonged in renal impairment (up to 24 hours in severe cases)
Terminal elimination half-life is 2.5-3 hours in adults with normal renal function; increased to up to 10-15 hours in severe renal impairment (CrCl <30 mL/min). Clinically, this supports 8-hourly dosing intervals in normal renal function, with extended intervals in renal impairment.
Renal (60-70% unchanged), biliary/fecal (20-30%)
Renal excretion accounts for 90-100% of elimination, primarily as the parent drug via glomerular filtration and tubular secretion. Urinary excretion: 90-100% unchanged. Fecal/biliary: negligible (<2%).
Category C
Category C
Antibiotic
Antibiotic